| Drug Type CAR-T | 
| Synonyms- | 
| Target | 
| Action inhibitors | 
| Mechanism DR5 inhibitors(Tumor necrosis factor receptor superfamily member 10B inhibitors) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhasePendingPhase 2 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Esophageal Carcinoma | Phase 2 | China  | 01 Sep 2019 | |
| Glioma | Phase 2 | China  | 01 Sep 2019 | |
| Hepatocellular Carcinoma | Phase 2 | China  | 01 Sep 2019 | |
| Stomach Cancer | Phase 2 | China  | 01 Sep 2019 | 





